Edwards Lifesciences (EW) CEO sells 22,430 shares, exercises options and makes gifts

Rhea-AI Filing Summary

Edwards Lifesciences CEO Bernard J. Zovighian reported several share transactions. On February 12, 2026, he exercised employee stock options covering 25,350 shares of common stock at an exercise price of $59.2567 per share. On the same day, he sold 2,532 shares at a weighted average price of $77.1287 and 19,898 shares at a weighted average price of $76.6133 in open-market transactions.

On February 13, 2026, he reported bona fide gifts of 2,920 shares of common stock at $0.0000 per share in a direct account and 2,920 shares reflected as indirectly held "By Trust." After these transactions, he directly held 80,976 shares, with an additional 11,516.5511 shares held indirectly by a trust and 3,655.5854 shares represented in his 401(k) plan.

Insights

Equity compensation and insider-trading analyst

CEO exercises options, sells shares, and makes gifts in routine Form 4 activity.

The CEO of Edwards Lifesciences exercised employee stock options for 25,350 shares at an exercise price of $59.2567, then sold 22,430 shares of common stock in open-market transactions at weighted average prices around the high $70 range. These are typical follow-on sales after option exercises.

He also reported bona fide gifts totaling 5,840 shares, split between a direct account and shares held "By Trust," and continues to own stock directly, through a trust, and via a 401(k). The filing does not indicate any change in role or strategy, so the information mainly updates ownership records rather than signaling a clear shift in outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zovighian Bernard J

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		M		25,350	A	$59.2567	106,326	D
Common Stock	02/12/2026		S		2,532	D	$77.1287(1)	103,794	D
Common Stock	02/12/2026		S		19,898	D	$76.6133(2)	83,896	D
Common Stock	02/13/2026		G		2,920	D	$0.0000	80,976	D
Common Stock	02/13/2026		G		2,920	A	$0.0000	11,516.5511	I	By Trust
Common Stock								3,655.5854(3)	I	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	02/12/2026		M			25,350	(4)	05/07/2026	Common Stock	25,350	$0.0000	0.0000	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $77.080 to $77.225 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

2. This transaction was executed in multiple trades at prices ranging from $76.080 to $77.075 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

3. Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

4. These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Edwards Lifesciences (EW) CEO Bernard Zovighian report?

Bernard Zovighian reported exercising options for 25,350 shares, selling 22,430 shares of Edwards Lifesciences common stock in open-market transactions, and making bona fide gifts totaling 5,840 shares. These moves update his direct and indirect ownership positions without indicating any role change.

At what prices did the Edwards Lifesciences (EW) CEO sell his shares?

He sold 2,532 shares at a weighted average of $77.1287 and 19,898 shares at a weighted average of $76.6133. The filing notes these were executed in multiple trades within disclosed price ranges, with full trade details available on request.

How many Edwards Lifesciences (EW) shares did the CEO acquire through option exercise?

He acquired 25,350 shares of Edwards Lifesciences common stock by exercising employee stock options with an exercise price of $59.2567 per share. These options were originally granted under the company’s long-term stock incentive compensation program.

What stock gifts did the Edwards Lifesciences (EW) CEO disclose in this Form 4?

He reported bona fide gifts of 2,920 shares of common stock in a direct account and 2,920 shares associated with an indirect holding "By Trust," both at a stated price of $0.0000 per share. These gifts are classified as non-sale dispositions.

How many Edwards Lifesciences (EW) shares does the CEO own after these transactions?

Following the reported transactions, he directly owns 80,976 shares of common stock, with an additional 11,516.5511 shares held indirectly through a trust and 3,655.5854 shares represented in his 401(k) plan, according to the filing’s ownership table.

What is the nature of the Edwards Lifesciences (EW) CEO’s indirect share ownership?

The filing shows indirect ownership of 11,516.5511 shares of common stock labeled "By Trust" and 3,655.5854 shares through a 401(k) plan. These entries indicate shares held via a trust structure and retirement plan, rather than in a personal brokerage account.